Michael A. Postow, MD

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, a medical oncologist and chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center in New York, New York, discusses available targeted agents for 

-mutant melanoma and ongoing clinical questions about treating the disease.

During the Physician’s Education Resource® 18th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® held in January 2022, Postow spoke to a room of peers about this topic. His talk focused on the past, present, and future of BRAF-directed treatment. During the podcast discussion with host, Nichole Tucker of Targeted Oncology™, the discussion was expanding to dive into topics like; the efficacy of FDA-approve BRAF targeted therapies, the most recent FDA approval and its impact, exploring approved agents in new treatment settings, and other key druggable targets in melanoma.

During the talk, Postow also touches on the main clinical questions that oncologists still have about treating patients with 

-mutant melanoma and what research is aiming to provide answers in the near future.

Podcasts

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

A Look Inside the Toolbox for BRAF-Mutant Metastatic Melanoma

Michael A. Postow, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, shares advice to community oncologists on managing the 

In many cases, these treatments are life-saving medications, Postow says. However, it is important to recognize when a patient is experiencing side effects from the treatment so that it can be modified in order to best support the patient.

Videos

Michael A. Postow, MD, shares advice to community oncologists on managing the side effects of immunotherapy in patients with melanoma.

Managing Immunotherapy Toxicities in Melanoma

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses BRAF and MEK inhibitor combinations studies in melanoma.

COMBI-AD and BRIM8 Studies in Melanoma

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the results of the COMBI-AD study and the CheckMate-238 study will impact the care of patients with melanoma.

How the Results of COMBI-AD and CheckMate-238 Will Impact Melanoma Care

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses targets beyond PD-1 in melanoma.

Targeting Beyond PD-1 in Melanoma

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering, discusses the need for further investigation into targeted agent combinations due to high rates of toxicities in patients with melanoma. Postow cites the combination of vemurafenib and ipilimumab as one that produced a high rate of liver inflammation and skin rash in patients, which was then deemed not to be given to patients outside of clinical trials.

Postow cites the combination of vemurafenib and ipilimumab as one that produced a high rate of liver inflammation and skin rash in patients, which was then deemed not to be given to patients outside of clinical trials.

Michael A. Postow, MD | Authors

Articles

A Look Inside the Toolbox for BRAF-Mutant Metastatic Melanoma

Managing Immunotherapy Toxicities in Melanoma

COMBI-AD and BRIM8 Studies in Melanoma

How the Results of COMBI-AD and CheckMate-238 Will Impact Melanoma Care

Targeting Beyond PD-1 in Melanoma

Dr. Michael Postow on the Toxicities of Melanoma-Treating Targeted Therapy Combinations